BridgeBio Oncology Therapeutics (BBOT) Balance Sheet: Assets & Liabilities

BridgeBio Oncology Therapeutics (BBOT) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), BridgeBio Oncology Therapeutics reported total assets of $448.38M and total liabilities of $37.28M. Shareholders' equity was $411.10M, up 117.8% from $188.72M a year earlier. Total debt stood at $2.77M against $425.46M in cash and short-term investments, a net cash position of $422.69M. That puts debt-to-equity at 0.01, compared with 0.00 a year earlier.

BridgeBio Oncology Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for BridgeBio Oncology Therapeutics, Inc. (BBOT) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Current Assets
Cash and Cash Equivalents	373.69	1.70	0.25	0.00	0.00	-
Short-Term Investments	51.77	0.00	0.00	0.00	0.00	-
Cash & Short-Term Investments	425.46	1.70	0.25	0.00	0.00	-
Accounts Receivable	0.39	0.00	1.72	0.00	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	-0.39	0.25	1.96	0.00	0.00	-
Total Current Assets	425.46	1.95	3.94	0.00	0.00	-
Non-Current Assets
Property, Plant & Equipment (Net)	0.00	0.00	0.60	0.00	0.00	0.00
Long-Term Investments	0.13	192.45	0.00	0.00	0.00	0.00
Other Non-Current Assets	22.79	0.03	1.41	0.14	0.14	-
Total Non-Current Assets	22.92	192.47	2.01	0.14	0.14	-
Total Assets	448.38	194.42	5.94	0.14	0.14	-
Current Liabilities
Accounts Payable	1.37	0.00	0.58	0.00	0.00	0.00
Short-Term Debt	0.52	0.00	0.07	0.04	0.04	0.06
Accrued Liabilities	26.87	9.10	3.54	-	-	-
Other Current Liabilities	33.15	0.19	0.33	0.17	0.13	-
Total Current Liabilities	35.04	0.19	16.78	0.17	0.16	-
Non-Current Liabilities
Long-Term Debt	2.24	0.00	0.00	0.00	0.00	0.00
Other Non-Current Liabilities	0.00	5.52	0.00	0.00	0.00	-
Total Non-Current Liabilities	2.24	5.52	104.81	0.00	0.00	-
Total Liabilities	37.29	5.71	121.58	0.17	0.16	-
Stockholders' Equity
Common Stock	0.01	192.45	0.00	0.00	0.00	0.00
Retained Earnings	-356.57	-3.73	-148.25	-0.05	-0.04	0.00
Accumulated Other Comprehensive Income	0.02	0.00	0.00	0.00	0.00	0.00
Additional Paid-in Capital	767.64	0.00	32.61	0.02	0.02	112.48
Shares Outstanding	79.99	79.20	79.20	-	-	-
Total Stockholders' Equity	411.10	188.72	-115.64	-0.02	-0.02	112.48
Total Liabilities & Equity	448.38	194.42	5.94	0.14	0.14	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About BridgeBio Oncology Therapeutics Balance Sheet

How much debt does BridgeBio Oncology Therapeutics have?

BridgeBio Oncology Therapeutics had total debt of $2.77M as of Dec 31, 2025, against $425.46M in cash and short-term investments. Its debt-to-equity ratio was 0.01. Total debt was $0.00 a year earlier.

What are BridgeBio Oncology Therapeutics's total assets?

BridgeBio Oncology Therapeutics reported total assets of $448.38M as of Dec 31, 2025, up 130.6% from $194.42M a year earlier. Total liabilities were $37.28M.

What is BridgeBio Oncology Therapeutics's shareholders' equity?

BridgeBio Oncology Therapeutics's shareholders' equity was $411.10M as of Dec 31, 2025, or about $5.14 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition